Who are LEV's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Keppra, intravenous levetireacetam, Oral levetiracetam, Standard dose topiramate, Carbamazepine-Implant, Standard dose levetiracetam.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lev.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

LEV — Competitive Intelligence Brief

LEV (LEV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiepileptic agent. Area: Neurology.

marketed Antiepileptic agent SV2A (synaptic vesicle glycoprotein 2A) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

LEV (LEV) — GlaxoSmithKline. LEV (levetiracetam) reduces neuronal excitability and seizure propagation through binding to synaptic vesicle protein SV2A.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
LEV TARGET	LEV	GlaxoSmithKline	marketed	Antiepileptic agent	SV2A (synaptic vesicle glycoprotein 2A)
Keppra	levetiracetam	Generic (originally UCB Pharma)	marketed	Antiepileptic agent	Synaptic vesicle protein SV2A	1999-11-30
intravenous levetireacetam	intravenous levetireacetam	ayesha tariq	marketed	Antiepileptic agent	SV2A (synaptic vesicle protein 2A)
Oral levetiracetam	Oral levetiracetam	Children's Hospital of Fudan University	marketed	Antiepileptic agent	SV2A (synaptic vesicle protein 2A)
Standard dose topiramate	Standard dose topiramate	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase
Carbamazepine-Implant	Carbamazepine-Implant	University of Sao Paulo	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels
Standard dose levetiracetam	Standard dose levetiracetam	Mario Negri Institute for Pharmacological Research	marketed	Antiepileptic agent	SV2A (synaptic vesicle protein 2A)

Recent regulatory actions (last 90 days)

2026-04-08 — Keppra · FDA · approved · US · Generic (originally UCB Pharma)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-09-03 — Keppra · 8163306 · Formulation · US
2027-10-31 — Keppra · 8431156 · Formulation · US
2027-10-31 — Keppra · 8470367 · Formulation · US
2028-09-17 — Keppra · 7858122 · Formulation · US
2031-06-07 — Keppra · 8802142 · Formulation · US
2031-12-07 — Keppra · 8802142*PED · Compound · US
2034-03-14 — Keppra · 11160786 · Formulation · US
2034-03-14 — Keppra · 9669009 · Method of Use · US
2034-03-14 — Keppra · 9339489 · Formulation · US

Sponsor landscape (Antiepileptic agent class)

Children's Hospital of Fudan University · 1 drug in this class
Generic (originally UCB Pharma) · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
Mario Negri Institute for Pharmacological Research · 1 drug in this class
Richard H. Haas · 1 drug in this class
ayesha tariq · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LEV — Competitive Intelligence Brief. https://druglandscape.com/ci/lev. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab